Enanta Pharmaceuticals, Inc. ENTA
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) is an infectious disease drug developer. Its lead program, Zelicapavir (EDP-938), is in Phase 2 for Respiratory syncytial virus (RSV). Its next catalyst on record is Zelicapavir RESOLVE: Study initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Zelicapavir RESOLVE — Study initiation (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zelicapavir (RESOLVE Phase 2b/3, high-risk adults) | RSV | small molecule | Phase 2 |
| Zelicapavir (LOTUS pediatric) | RSV | small molecule | Phase 2 |
| EDP-323 | RSV | small molecule | Phase 2 |
| EDP-978 (KIT) | immunology | small molecule | Phase 1 |
| EPS-3903 (STAT6) | immunology | small molecule | Pre-clinical |
| MRGPRX2 candidate | immunology | small molecule | Pre-clinical |
Recent results and decisions
- Aug 10, 2026started Dosing began in LOTUS, a ~150-patient Phase 2b pediatric zelicapavir trial in RSV; topline expected 2027.
Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027
Filing - Nov 17, 2025mixed RSVHR Phase 2b: primary endpoint (LRTD symptom resolution) showed no effect, but 13-symptom resolution was 2.2 days faster overall (6.7 days in HR3), PGI-S 2 days faster (significant), lower hospitalization rate.
no effect was observed on the time to resolution of the LRTD subset of four symptoms to mild, which was the primary endpoint.
Filing - Nov 17, 2025positive EDP-323 Phase 2a challenge PEP analysis: 0/45 EDP-323 recipients infected vs 6/23 (26%) on placebo, p<0.001 (IDWeek 2025).
26% (6/23) of those who received placebo became infected versus 0% (0/45) of EDP-323 recipients (p<0.001).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.